IgAN is a rare form of chronic kidney disease in which immunoglobulin A (IgA) becomes trapped in the glomeruli of the kidneys, resulting in damage and scarring. While the condition has traditionally been managed using conventional supportive care, over the past decade, treatment has moved towards disease-modifying therapies that address disease progression more directly.

Clinical guidance, most prominently from KDIGO1, is evolving alongside these advances, helping clinicians assess risk and navigate a growing range of management options. Indeed, findings from Ipsos’ Conference Research Assessment Monitors following both the ASN 2025 and ERA 2026 congresses showed that nephrologists frequently cited expanding treatment approaches and earlier intervention among their key IgAN learnings taken from the events.

As in other disease areas experiencing treatment innovation, this progress raises an important question: where might patients encounter delays on the path to an IgAN diagnosis and treatment and what could help them receive appropriate care sooner?